Literature DB >> 26260802

Everolimus-based therapy in patients with hormone receptor-positive, HER2(-) advanced breast cancer: management considerations.

Lucia Del Mastro1, Marina Cazzaniga2, Paolo Solidoro3, Daniele Generali4, Giulia Bianchi5, Franco Testore4, Sabino De Placido6.   

Abstract

Entities:  

Keywords:  adverse events; breast cancer; compliance; dosing; everolimus; management; multidisciplinary follow-up; toxicity

Mesh：

Substances：

Year:  2015        PMID： 26260802     DOI： 10.2217/fon.15.134

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


× No keyword cloud information.
  1 in total

1.  Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.

Authors:  Daniele Generali; Filippo Montemurro; Roberto Bordonaro; Antonino Mafodda; Sante Romito; Andrea Michelotti; Pierluigi Piovano; Maria Teresa Ionta; Claudia Bighin; Donata Sartori; Antonio Frassoldati; Marina Elena Cazzaniga; Ferdinando Riccardi; Franco Testore; Patrizia Vici; Carlo Antonio Barone; Alessio Schirone; Federico Piacentini; Franco Nolè; Annamaria Molino; Luciano Latini; Edda Lucia Simoncini; Fausto Roila; Francesco Cognetti; Francesco Nuzzo; Jennifer Foglietta; Alessandro Marco Minisini; Francesca Goffredo; Giuseppe Portera; Gilda Ascione; Gabriella Mariani
Journal:  Oncologist       Date:  2017-04-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.